Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer

Prostate

Volumn 53, Issue 2, 2002, Pages 109-117

  Gulley, James ^a   Chen, Alice P ^a   Dahut, William ^a   Arlen, Philip M ^a   Bastian, Anne ^a   Steinberg, Seth M ^a   Tsang, Kwong ^a   Panicali, Dennis ^b   Poole, Diane ^a   Schlom, Jeffrey ^a   Hamilton, J Michael ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Therion Biologics Corporation   (United States)

Author keywords

Prostate cancer; PSA; T cells; Vaccine

Indexed keywords

ANDROGEN; CANCER VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG FORMULATION; DRUG SAFETY; ECZEMA; ERYTHEMA; FEVER; HUMAN; IMMUNE RESPONSE; IMMUNOREACTIVITY; IN VITRO STUDY; MALE; MAXIMUM TOLERATED DOSE; METASTASIS; NAUSEA; PAIN; PHASE 1 CLINICAL TRIAL; POSTVACCINAL ENCEPHALITIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PYODERMA GANGRENOSUM; SKIN MANIFESTATION; SKIN TOXICITY; STEVENS JOHNSON SYNDROME; T LYMPHOCYTE; TOXICITY; TUMOR CELL; VACCINATION; VACCINIA VIRUS; VIRUS RECOMBINANT; VOMITING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; CANCER VACCINES; DISEASE PROGRESSION; HUMANS; IMMUNOTHERAPY, ACTIVE; INTERFERON TYPE II; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECOMBINANT PROTEINS; VACCINIA VIRUS;

EID: 0036787490     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10130     Document Type: Article

References (24)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002;52:23-47.
2. Correale P, Walmsley K, Nierod C, Zaremba S, Zhu M, Schlom J, Tsang KY. In vitro generation of human cytotoxic T lymphocytes specific for peptide derived from prostate specific antigen. J Natl Cancer Inst 1997;89:293-300.
3. Correale P, Walmsley K, Zaremba S, Zhu M, Schlom J, Tsang KY. Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide. J Immunol 1998;161:3186-3194.
4. Wei C, Storozynsky E, McAdam AJ, Yeh KY, Tilton BR, Willis RA, Barth RK, Looney RJ, Lord EM, Frelinger JG. Expression of human prostate-specific antigen (PSA) in a mouse tumor cell line reduces tumorigenicity and elicits PSA-specific cytotoxic T lymphocytes. Cancer Immunol Immunother 1996;42:362-368.
5. Schlom J, Panicali D. Recombinant poxvirus vaccines. In: Rosenberg SA, editor. Biologic therapy of cancer: principles and practices. 3rd ed. Philadelphia: JB Lippincott Co; 2000. p 686-694.
6. Hodge JW, Schlom J, Donohue SJ, Tomaszewski JE, Wheeler CW, Levine BS, Gritz L, Panicali D, Kantor JA. A recombinant vaccinia virus expressing human prostate-specific antigen (PSA): safety and immunogenicity in a non-human primate. Int J Cancer 1995;63:231-237.
7. Eder JP, Kantoff PW, Roper K, Xu GX, Bubley GJ, Boyden J, Gritz L, Mazzara G, Oh WK, Arlen P, Tsang KY, Panicali D, Schlom J, Kufe DW. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res 2000;6:1632-1638.
8. Sanda M, Smith D, Charles LG, Hwang C, Pienta KJ, Schlom J, Milenic D, Panicali D, Montie JE. Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology 1999; 53:260-266.
9. Centers for Disease Control. Vaccinia (smallpox) vaccine recommendation of the Immunization Practices Advisory Committee (ACIP). MMWR Morb Motal Wkly Rep 1991;40:1-10.
10. Arlen P, Tsang KY, Marshall JL, Chen A, Steinberg SM, Poole D, Hand PH, Schlom J, Hamilton JM. The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines. Cancer Immunol Immunother 2000;49:517-529.
11. Scheibenbogen C, Lee KH, Mayer S, Stevanovic S, Moebius U, Herr W, Rammensee HG, Keilholz U. A sensitive ELISPOT assay for detection of CD8+ T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients. Clin Cancer Res 1997;3:221-226.
12. Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM, Schlom J. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 1995;87:982-990.
13. McLaughlin JP, Schlom J, Kantor JA, Greiner J. Improved immunotherapy of a recombinant CEA vaccinia vaccine when given in combination with Interleukin-2. Cancer Res 1996;56: 2361-2367.
14. Hodge JW, McLaughlin JP, Kantor JA, Schlom J. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant nonreplicating avian pox virus to enhance T-cell immunity and antitumor responses. Vaccine 1997;15:759-768.
15. Hodge JW, Sabzevari H, Yafal AG, Gritz L, Lorenz MGO, Schlom J. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res 1999;59:5800-5807.
16. Kalus RM, Kantor JA, Gritz L, Gomez Yafal A, Mazzara GP, Schlom J, Hodge JW. The use of combination vaccinia vaccines and dual-gene vaccinia vaccines to enhance antigen-specific T-cell immunity via T-cell costimulation. Vaccine 1999;17:893-903.
17. Kass E, Panicali DL, Mazzara G, Schlom J, Greiner JW. Granulocyte-macrophage colony-stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant. Cancer Res 2001;61:206-214.
18. Grosenbach DW, Barrientos JC, Schlom J, Hodge JW. Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects. Cancer Res 2001;61:4497-4505.
19. Murata K, Garcia-Sestre A, Tsuji M, Rodrigues M, Rodriguez D, Rodriguez JR, Nussenzweig RS, Palese P, Esteban M, Zavala F. Characterization in vivo primary and secondary CD8+ T cell responses induced by recombinant influenza and vaccinia viruses. Cell Immunol 1996;173:96-107.
20. Irvine KR, Chamberlain RS, Shulman EP, Surman DR, Rosenberg SA, Restifo NP. Enhancing the efficiency of recombinant anti-cancer vaccines with prime/boost regimens that employ 2 different vectors. J Natl Cancer Inst 1997;89:1595-1604.
21. Marshall JL, Hoyer RJ, Toomey MA, Faraguna K, Chang P, Richmond E, Pedicano JE, Gehan E, Peck RA, Arlen P, Tsang KY, Schlom J. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol 2000;18:3964-3973.
22. Warren TL, Weiner GJ. Uses of granulocyte-macrophage colony-stimulating factor in vaccine development. Curr Opin Hematol 2000;7:168-173.
23. Arlen PM, Gulley J, Novik L, Hamilton JM, Bastian A, Pannicali D, Palena C, Tsang KY, Schlom J, Dahut WL. A randomized phase II trial of either vaccine therapy (recombinant pox viruses expressing PSA and the B7.1 costimulatory molecule) versus hormone therapy (nilutamide) in patients (pts) with hormone refractory prostate cancer and no radiographic evidence of disease (abstract). In, Program/Proceedings of the Thirty-Eighth Annual Meeting of the American Society of Clinical Oncology, Orlando, FL: American Society of Clinical Oncology 2002;21:728a.
24. Gulley JL, Arlen PM, Bastian A, Coleman N, Hamilton M, Tsang K, Panicali D, Douglas R, Sullivan FJ, Schlom AJ, Dahut WL. A phase II study of prostate specific antigen (PSA)-based vaccine in patients with localized prostate cancer receiving standard radiotherapy (RT) (abstract). In, Program/Proceedings of the Thirty-Eighth Annual Meeting of the American Society of Clinical Oncology, Orlando, FL: American Society of Clinical Oncology 2002;21:1814a.